Screening of potential biomarkers in uterine leiomyomas disease via gene expression profiling analysis

Liu,Xuhui; Liu,Yanfei; Zhao,Jingrong; Liu,Yan

doi:10.3892/mmr.2018.8756

Screening of potential biomarkers in uterine leiomyomas disease via gene expression profiling analysis

Authors:
- Xuhui Liu
- Yanfei Liu
- Jingrong Zhao
- Yan Liu
View Affiliations

Affiliations: Department of Gynaecology, Weifang Yidu Central Hospital, Weifang, Shandong 262500, P.R. China, Department of Gynaecology and Obstetrics, Weifang Brain Hospital in Shandong, Weifang, Shandong 261000, P.R. China, Department of Medical Record Information Section, The Chinese People's Liberation Army 89 Hospital, Weifang, Shandong 261021, P.R. China, Department of Gynecology, Weifang People's Hospital, Weifang, Shandong 261041, P.R. China
Published online on: March 15, 2018 https://doi.org/10.3892/mmr.2018.8756
Pages: 6985-6996
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to screen potential biomarkers for uterine leiomyomas disease, particularly target genes associated with the mediator of RNA polymerase II transcription subunit 12 (MED12) mutation. The microarray data of GSE30673, including 10 MED12 wild-type myometrium, 8 MED12 mutation leiomyoma and 2 MED12 wild-type leiomyoma samples, were downloaded from the Gene Expression Omnibus database. Compared with myometrium samples, differently-expressed genes (DEGs) in the MED12 mutation and wild-type leiomyoma samples were identified using the Limma package. The two sets of DEGs obtained were intersected to screen common DEGs. The DEGs in the MED12 mutation and wild-type leiomyoma samples, and common DEGs were defined as group A, B and C. Gene Ontology (GO) and pathway enrichment analyses were performed using the Database for Annotation, Visualization and Integrated Discovery online tool. Based on the Kyoto Encyclopedia of Genes and Genomes database, pathway relation networks were constructed. DEGs in GO terms and pathways were intersected to screen important DEGs. Subsequently, a gene co‑expression network was constructed and visualized using Cytoscape software. Reverse transcription‑quantitative polymerase chain reaction was used to detect the expression levels of important DEGs. A total of 1,258 DEGs in group A were screened, and enriched for extracellular matrix (ECM) organization and ECM‑receptor interaction. In addition, a total of 1,571 DEGs in group B were enriched for cell adhesion. Furthermore, 391 DEGs were involved in extracellular matrix organization. Pathway relation networks of group A, B and C were constructed with nodes of 48, 39, and 28, respectively. Finally, 135 important DEGs were obtained, including Acyl‑CoA synthetase medium‑chain family member 3, protein S (α) (PROS1) and F11 receptor. A gene co‑expression network with 68 nodes was constructed. The expression of caspase 1 (CASP1) and aldehyde dehydrogenase 1 family member A1 (ALDH1A1) was significant higher in SK‑UT‑1 compared with that in PHM1‑31 cells, while the expression of PROS1 was significant lower in SK‑UT‑1 cells. These results that CASP1, ALDH1A1 and PROS1 may be potential biomarkers for uterine leiomyomas. Furthermore, hematopoietic prostaglandin D synthase and carbonyl reductase 3 (CBR3) may be particular genes associated with the MED12 mutation in this disease.

View Figures

View References

1	Moroni RM, Vieira CS, Ferriani RA, Candido-dos-Reis FJ and Brito LGO: Pharmacological treatment of uterine fibroids. Ann Med Health Sci Res. 4 Suppl 3:S185–S192. 2014. View Article : Google Scholar : PubMed/NCBI
2	Razavi MK, Hwang G, Jahed A, Modanlou S and Chen B: Abdominal myomectomy versus uterine fibroid embolization in the treatment of symptomatic uterine leiomyomas. AJR Am J Roentgenol. 180:1571–1575. 2003. View Article : Google Scholar : PubMed/NCBI
3	He X: Estrogen receptor and progesterone receptor expressions at the edge of the targeted region of uterus fibroids ablated by acoustic power. J Chongqing Med Univ. 36:5–7. 2011.
4	Mäkinen N, Mehine M, Tolvanen J, Kaasinen E, Li Y, Lehtonen HJ, Gentile M, Yan J, Enge M, Taipale M, et al: MED12, the mediator complex subunit 12 gene, is mutated at high frequency in uterine leiomyomas. Science. 334:252–255. 2011. View Article : Google Scholar : PubMed/NCBI
5	Raimundo N, Vanharanta S, Aaltonen LA, Hovatta I and Suomalainen A: Downregulation of SRF-FOS-JUNB pathway in fumarate hydratase deficiency and in uterine leiomyomas. Oncogene. 28:1261–1273. 2009. View Article : Google Scholar : PubMed/NCBI
6	Shen Y, Wu Y, Lu Q, Zhang P and Ren M: Transforming growth factor-β signaling pathway cross-talking with ERα signaling pathway on regulating the growth of uterine leiomyoma activated by phenolic environmental estrogens in vitro. Tumour Biol. 37:455–462. 2016. View Article : Google Scholar : PubMed/NCBI
7	Klotzbücher M, Wasserfall A and Fuhrmann U: Misexpression of wild-type and truncated isoforms of the high-mobility group I proteins HMGI-C and HMGI(Y) in uterine leiomyomas. Am J Pathol. 155:1535–1542. 1999. View Article : Google Scholar : PubMed/NCBI
8	Chuang TY, Min J, Wu HL, McCrary C, Layman LC, Diamond MP, Azziz R, Al-Hendy A and Chen YH: Berberine inhibits uterine leiomyoma cell proliferation via downregulation of cyclooxygenase 2 and pituitary tumor-transforming gene 1. Reprod Sci. 24:1005–1013. 2017. View Article : Google Scholar : PubMed/NCBI
9	Gautier L, Cope L, Bolstad BM and Irizarry RA: affy-analysis of Affymetrix GeneChip data at the probe level. Bioinformatics. 20:307–315. 2004. View Article : Google Scholar : PubMed/NCBI
10	Huan JL, Gao X, Xing L, Qin XJ, Qian HX, Zhou Q and Zhu L: Screening for key genes associated with invasive ductal carcinoma of the breast via microarray data analysis. Genet Mol Res. 13:7919–7925. 2014. View Article : Google Scholar : PubMed/NCBI
11	Chen L, Chu C, Lu J, Kong X, Huang T and Cai YD: Gene ontology and KEGG pathway enrichment analysis of a drug target-based classification system. PLoS One. 10:e01264922015. View Article : Google Scholar : PubMed/NCBI
12	Smoot ME, Ono K, Ruscheinski J, Wang PL and Ideker T: Cytoscape 2.8: New features for data integration and network visualization. Bioinformatics. 27:431–432. 2011. View Article : Google Scholar : PubMed/NCBI
13	Southby J, Murphy LM, Martin TJ and Gillespie MT: Cell-specific and regulator-induced promoter usage and messenger ribonucleic acid splicing for parathyroid hormone-related protein. Endocrinology. 137:1349–1357. 1996. View Article : Google Scholar : PubMed/NCBI
14	Commandeur AE, Styer AK and Teixeira JM: Epidemiological and genetic clues for molecular mechanisms involved in uterine leiomyoma development and growth. Hum Reprod Update. 21:593–615. 2015. View Article : Google Scholar : PubMed/NCBI
15	Kessel PdAHMGv, Pauwels PAA and Schoenmakers EFPM: Molecular genetic and functional characterization of signalling networks that govern the development of human uterine leiomyomas. IEEE International Symposium on Multiple-valued Logic. pp. 2331998;
16	Commandeur AE, Styer AK and Teixeira JM: Epidemiological and genetic clues for molecular mechanisms involved in uterine leiomyoma development and growth. Hum Reprod Update. 21:593–615. 2015. View Article : Google Scholar : PubMed/NCBI
17	Rice KE, Secrist JR, Woodrow EL, Hallock LM and Neal JL: Etiology, diagnosis, and management of uterine leiomyomas. J Midwifery Womens Health. 57:241–247. 2012. View Article : Google Scholar : PubMed/NCBI
18	Thirupathi A, Elango T, Subramanian S and Gnanaraj P: Methotrexate regulates Th-1 response by suppressing caspase-1 and cytokines in psoriasis patients. Clin Chim Acta. 453:164–169. 2016. View Article : Google Scholar : PubMed/NCBI
19	Gloria-Bottini F, Pietropolli A, Ammendola M, Saccucci P and Bottini E: PTPN22 and uterine leiomyomas. Eur J Obstet Gynecol Reprod Biol. 185:96–98. 2015. View Article : Google Scholar : PubMed/NCBI
20	Christman GM, Tang H, Ahmad I and Stribley JM: Differential expression of the Notch signal transduction pathway: Ligands, receptors and Numb in uterine leiomyomas vs. myometrium. Fertil Steril. 88 Suppl 1:S722007. View Article : Google Scholar
21	Zaitseva M, Vollenhoven BJ and Rogers PAW: 443. The fibroblast-smooth muscle cell relationship is altered in uterine leiomyoma. Reprod Fertil Dev. 20:1232008. View Article : Google Scholar
22	Shveiky D and Rojansky N: 255: Alcohol has a permissive effect on the growth of uterine leiomyomata cells in tissue cultures. J Minim Invasive Gynecol. 14 Suppl:S92–S93. 2007. View Article : Google Scholar
23	Luo X and Chegini N: The expression and potential regulatory function of microRNAs in the pathogenesis of leiomyoma. Semin Reprod Med. 26:500–514. 2008. View Article : Google Scholar : PubMed/NCBI
24	Moreb JS, Baker HV, Chang LJ, Amaya M, Lopez MC, Ostmark B and Chou W: ALDH isozymes downregulation affects cell growth, cell motility and gene expression in lung cancer cells. Mol Cancer. 7:872008. View Article : Google Scholar : PubMed/NCBI
25	Takeda T, Sakata M, Isobe A, Miyake A, Nishimoto F, Ota Y, Kamiura S and Kimura T: Relationship between metabolic syndrome and uterine leiomyomas: A case-control study. Gynecol Obstet Invest. 66:14–17. 2008. View Article : Google Scholar : PubMed/NCBI
26	Castoldi E and Hackeng TM: Regulation of coagulation by protein S. Curr Opin Hematol. 15:529–536. 2008. View Article : Google Scholar : PubMed/NCBI
27	Fang BQ and Zhang JW: Molecular mechanisms of protein S deficiency caused by a novel nonsense mutation. Chin J Vasc Surg. 2:32–35. 2015.
28	Cunin P, Beauvillain C, Miot C, Augusto JF, Preisser L, Blanchard S, Pignon P, Scotet M, Garo E, Fremaux I, et al: Clusterin facilitates apoptotic cell clearance and prevents apoptotic cell-induced autoimmune responses. Cell Death Dis. 7:e22152016. View Article : Google Scholar : PubMed/NCBI